Cargando…
[Corrigendum] Fully human VEGFR2 monoclonal antibody BC001 attenuates tumor angiogenesis and inhibits tumor growth
Autores principales: | Xuan, Zi-Xue, Li, Lin-Na, Zhang, Qi, Xu, Cheng-Wang, Yang, De-Xuan, Yuan, Ye, An, Ying-Hong, Wang, Shan-Shan, Li, Xiao-Wen, Yuan, Shou-Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631764/ https://www.ncbi.nlm.nih.gov/pubmed/37888731 http://dx.doi.org/10.3892/ijo.2023.5583 |
Ejemplares similares
-
Evidence for G-quadruplex in the promoter of VEGFR-2 and its targeting to inhibit tumor angiogenesis
por: Salvati, E., et al.
Publicado: (2014) -
Corrigendum to “Molecular Characterization of a Fully Human Chimeric T-Cell Antigen Receptor for Tumor-Associated Antigen EpCAM”
por: Shirasu, Naoto, et al.
Publicado: (2015) -
Corrigendum to “ATF4- and CHOP-Dependent Induction of FGF21 through Endoplasmic Reticulum Stress”
por: Wan, Xiao-shan, et al.
Publicado: (2018) -
Corrigendum to “New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy”
por: Guo, Qiujun, et al.
Publicado: (2018) -
Corrigendum to “The Transcription Factor Bach1 Suppresses the Developmental Angiogenesis of Zebrafish”
por: Jiang, Li, et al.
Publicado: (2018)